Hypereosinophilic syndromes: A multicenter, retrospective analysis of clinical characteristics and response to therapy

DSpace/Manakin Repository

Hypereosinophilic syndromes: A multicenter, retrospective analysis of clinical characteristics and response to therapy

Citable link to this page

 

 
Title: Hypereosinophilic syndromes: A multicenter, retrospective analysis of clinical characteristics and response to therapy
Author: Ogbogu, Princess U.; Bochner, Bruce S.; Butterfield, Joseph H.; Gleich, Gerald J.; Huss-Marp, Johannes; Kahn, Jean Emmanuel; Leiferman, Kristin M.; Nutman, Thomas B.; Pfab, Florian; Ring, Johannes; Rothenberg, Marc E.; Roufosse, Florence; Sajous, Marie-Helene; Sheikh, Javed; Simon, Dagmar; Simon, Hans-Uwe; Stein, Miguel L.; Wardlaw, Andrew; Weller, Peter Fahey; Klion, Amy D.

Note: Order does not necessarily reflect citation order of authors.

Citation: Ogbogu, Princess U., Bruce S. Bochner, Joseph H. Butterfield, Gerald J. Gleich, Johannes Huss-Marp, Jean Emmanuel Kahn, Kristin M. Leiferman, et al. 2009. Hypereosinophilic syndromes: A multicenter, retrospective analysis of clinical characteristics and response to therapy. Journal of Allergy and Clinical Immunology 124, no. 6: 1319–1325.e3. doi:10.1016/j.jaci.2009.09.022.
Full Text & Related Files:
Abstract: Background:

Hypereosinophilic syndrome (HES) is a heterogeneous group of rare disorders defined by persistent blood eosinophilia ≥1.5 × 109/L, absence of a secondary cause, and evidence of eosinophil-associated pathology. With the exception of a recent multicenter trial of mepolizumab (anti–IL-5 mAb), published therapeutic experience has been restricted to case reports and small case series.

Objective:

The purpose of the study was to collect and summarize baseline demographic, clinical, and laboratory characteristics in a large, diverse cohort of patients with HES and to review responses to treatment with conventional and novel therapies.

Methods:

Clinical and laboratory data from 188 patients with HES, seen between January 2001 and December 2006 at 11 institutions in the United States and Europe, were collected retrospectively by chart review.

Results:

Eighteen of 161 patients (11%) tested were Fip1-like 1–platelet-derived growth factor receptor α (FIP1L1-PDGFRA) mutation—positive, and 29 of 168 patients tested (17%) had a demonstrable aberrant or clonal T-cell population. Corticosteroid monotherapy induced complete or partial responses at 1 month in 85% (120/141) of patients with most remaining on maintenance doses (median, 10 mg prednisone equivalent daily for 2 months to 20 years). Hydroxyurea and IFN-α (used in 64 and 46 patients, respectively) were also effective, but their use was limited by toxicity. Imatinib (used in 68 patients) was more effective in patients with the FIP1L1-PDGFRA mutation (88%) than in those without (23%; P < .001).

Conclusion:

This study, the largest clinical analysis of patients with HES to date, not only provides useful information for clinicians but also should stimulate prospective trials to optimize treatment of HES.
Published Version: doi:10.1016/j.jaci.2009.09.022
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829669/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:27377612
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters